| Species |
Human |
| Protein Construction |
CD24-VLP (Ser27-Gly59)
Accession # P25063-1 |
|
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CD24-VLP, Human at 0.5μg/ml (100μl/well) on the plate can bind Anti-CD24 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
5.0 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 5.0 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized CD24-VLP, Human at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-CD24 Antibody, hFc Tag with the EC50 of 19.4 ng/ml determined by ELISA.
| Target Background |
CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers. |
| Synonyms |
CD 24; CD24 molecule; CD24A; FLJ22950; FLJ43543; MGC75043 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
